Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Partially Blinded Study to Assess Reactogenicity & Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ in Healthy Infants After a Hepatitis B Birth Dose

NCT00317187 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00317187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Partially Blinded Study to Assess Reactogenicity & Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ in Healthy Infants After a Hepatitis B Birth Dose
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 8, 2004
Completion date
January 16, 2005
Enrollment
500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, hepatitis b, tetanus, whole cell pertussis